Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD. Barb D, Kalavalapalli S, Leiva EG, Bril F, et al. J Hepatol 2025 Jan 15:S0168-8278(25)00002-9. doi: 10.1016/j.jhep.2024.

Read + Share

Amedeo Smart

Independent Medical Education

Barb D, Kalavalapalli S, Leiva EG, Bril F, et al. Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD. J Hepatol 2025 Jan 15:S0168-8278(25)00002-9. doi: 10.1016/j.jhep.2024.
PMID: 39824443